INTRODUCTION: The nationwide Icelandic Cancer Registry (ICR) was established in 1954 and has been extensively used for research from the outset although formal quality assessment of the registry database has not previously been undertaken. In this paper we report the first formal evaluation of the comparability, validity, timeliness and completeness of the ICR. MATERIAL AND METHODS: Data from the ICR for the period 1955-2009 (41 994 cancer diagnoses) were used, applying established quantitative and semi-quantitative methods. In order to evaluate the completeness of the ICR, record linkage was performed between the ICR and the population-based Hospital Discharge Registry to identify potential missing cases for tumour diagnoses in 2000 and 2001. RESULTS: The registration is in accordance with internationally accepted standards. It has high validity, but random variation in rates is prominent in this small population. Record linkage with the Hospital Discharge Registry revealed that in addition to the 2459 cancers registered in 2000-2001, 21 cases were missing, indicating 99.15% completeness. Tumours of the central nervous system constituted 71%, and haematological malignancies 19% of these missing entries. DISCUSSION: The ICR has high completeness, validity and timeliness and is comparable to the cancer registries of the other Nordic Countries. As cancer registries have many important roles, it is of great importance that their data are at all times as complete and valid as possible. Thus the ICR aims to constantly improve and update the data gathering process.
INTRODUCTION: The nationwide Icelandic Cancer Registry (ICR) was established in 1954 and has been extensively used for research from the outset although formal quality assessment of the registry database has not previously been undertaken. In this paper we report the first formal evaluation of the comparability, validity, timeliness and completeness of the ICR. MATERIAL AND METHODS: Data from the ICR for the period 1955-2009 (41 994 cancer diagnoses) were used, applying established quantitative and semi-quantitative methods. In order to evaluate the completeness of the ICR, record linkage was performed between the ICR and the population-based Hospital Discharge Registry to identify potential missing cases for tumour diagnoses in 2000 and 2001. RESULTS: The registration is in accordance with internationally accepted standards. It has high validity, but random variation in rates is prominent in this small population. Record linkage with the Hospital Discharge Registry revealed that in addition to the 2459 cancers registered in 2000-2001, 21 cases were missing, indicating 99.15% completeness. Tumours of the central nervous system constituted 71%, and haematological malignancies 19% of these missing entries. DISCUSSION: The ICR has high completeness, validity and timeliness and is comparable to the cancer registries of the other Nordic Countries. As cancer registries have many important roles, it is of great importance that their data are at all times as complete and valid as possible. Thus the ICR aims to constantly improve and update the data gathering process.
Authors: Johanna E Torfadottir; Thor Aspelund; Unnur A Valdimarsdottir; Mary Frances Cotch; Laufey Tryggvadottir; Tamara B Harris; Vilmundur Gudnason; Hans-Olov Adami; Lorelei A Mucci; Edward L Giovannucci; Meir J Stampfer; Laufey Steingrimsdottir Journal: Cancer Causes Control Date: 2019-02-25 Impact factor: 2.506
Authors: Lara G Sigurdardottir; Unnur A Valdimarsdottir; Lorelei A Mucci; Katja Fall; Jennifer R Rider; Eva Schernhammer; Charles A Czeisler; Lenore Launer; Tamara Harris; Meir J Stampfer; Vilmundur Gudnason; Steven W Lockley Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-05 Impact factor: 4.254
Authors: Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Edward Giovannucci; Kathryn M Wilson; Thor Aspelund; Laufey Tryggvadottir; Lara G Sigurdardottir; Tamara B Harris; Lenore J Launer; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci Journal: Cancer Date: 2019-06-10 Impact factor: 6.860
Authors: V Stefansdottir; H Skirton; O Th Johannsson; H Olafsdottir; G H Olafsdottir; L Tryggvadottir; J J Jonsson Journal: Fam Cancer Date: 2019-04 Impact factor: 2.375
Authors: Simon N Stacey; Hannes Helgason; Sigurjon A Gudjonsson; Gudmar Thorleifsson; Florian Zink; Asgeir Sigurdsson; Birte Kehr; Julius Gudmundsson; Patrick Sulem; Bardur Sigurgeirsson; Kristrun R Benediktsdottir; Kristin Thorisdottir; Rafn Ragnarsson; Victoria Fuentelsaz; Cristina Corredera; Yolanda Gilaberte; Matilde Grasa; Dolores Planelles; Onofre Sanmartin; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Bjørn A Nexø; Anne Tjønneland; Kim Overvad; Jon G Jonasson; Laufey Tryggvadottir; Hrefna Johannsdottir; Anna M Kristinsdottir; Hreinn Stefansson; Gisli Masson; Olafur T Magnusson; Bjarni V Halldorsson; Augustine Kong; Thorunn Rafnar; Unnur Thorsteinsdottir; Ulla Vogel; Rajiv Kumar; Eduardo Nagore; José I Mayordomo; Daniel F Gudbjartsson; Jon H Olafsson; Kari Stefansson Journal: Nat Commun Date: 2015-04-09 Impact factor: 14.919
Authors: John Maret-Ouda; Karl Wahlin; Miia Artama; Nele Brusselaers; Martti Färkkilä; Elsebeth Lynge; Fredrik Mattsson; Eero Pukkala; Pål Romundstad; Laufey Tryggvadóttir; My von Euler-Chelpin; Jesper Lagergren Journal: JAMA Oncol Date: 2018-11-01 Impact factor: 31.777
Authors: Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Kathryn M Wilson; Laufey Steingrimsdottir; Thor Aspelund; Julie L Batista; Katja Fall; Edward Giovannucci; Lara G Sigurdardottir; Laufey Tryggvadottir; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci Journal: Int J Cancer Date: 2017-11-16 Impact factor: 7.396
Authors: Thorunn Rafnar; Gudbjorg R Sigurjonsdottir; Simon N Stacey; Gisli Halldorsson; Patrick Sulem; Luba M Pardo; Hannes Helgason; Stefan T Sigurdsson; Thorkell Gudjonsson; Laufey Tryggvadottir; Gudridur H Olafsdottir; Jon G Jonasson; Kristin Alexiusdottir; Asgeir Sigurdsson; Julius Gudmundsson; Jona Saemundsdottir; Jon K Sigurdsson; Hrefna Johannsdottir; Andre Uitterlinden; Sita H Vermeulen; Tessel E Galesloot; Dawn C Allain; Martin Lacko; Bardur Sigurgeirsson; Kristin Thorisdottir; Oskar T Johannsson; Fridbjorn Sigurdsson; Gunnar B Ragnarsson; Helgi Isaksson; Hronn Hardardottir; Tomas Gudbjartsson; Daniel F Gudbjartsson; Gisli Masson; Lambertus A M L Kiemeney; Amanda Ewart Toland; Tamar Nijsten; Wilbert H M Peters; Jon H Olafsson; Steinn Jonsson; Unnur Thorsteinsdottir; Gudmar Thorleifsson; Kari Stefansson Journal: J Natl Cancer Inst Date: 2018-09-01 Impact factor: 13.506